12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Company News  |  Deals

BioXpress Therapeutics, AET Group deal

BioXpress and the AET BioTech biosimilars business of generics company Alfred E. Tiefenbacher partnered to co-develop a biosimilar version of autoimmune drug adalimumab, a human mAb against tumor necrosis factor (TNF) alpha. AET BioTech will provide "committed long term"...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >